6 results match your criteria: "7-112 Clinical Sciences Building[Affiliation]"

Patients with Parkinson's Disease (PD) often suffer from cognitive decline. Accurate prediction of cognitive decline is essential for early treatment of at-risk patients. The aim of this study was to develop and evaluate a multimodal machine learning model for the prediction of continuous cognitive decline in patients with early PD.

View Article and Find Full Text PDF

Motor symptoms in Parkinson's disease are related to the interplay between cortical curvature and thickness.

Neuroimage Clin

March 2023

Department of Clinical Neurosciences, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, 3330 Hospital Dr NW, Calgary, AB T2N 1N4, Canada; Centre de recherche de l'Institut universitaire de gériatrie de Montréal, 4565 Chemin Queen Mary, Montréal, QC H3W 1W5, Canada; Department of Radiology, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada; Département de radiologie, radio-oncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Pavillon Roger-Gaudry, 2900 boulevard, Édouard-Montpetit, Montréal, QC H3T 1A4, Canada. Electronic address:

Introduction: Brain atrophy in Parkinson's disease occurs to varying degrees in different brain regions, even at the early stage of the disease. While cortical morphological features are often considered independently in structural brain imaging studies, research on the co-progression of different cortical morphological measurements could provide new insights regarding the progression of PD. This study's aim was to examine the interplay between cortical curvature and thickness as a function of PD diagnosis, motor symptoms, and cognitive performance.

View Article and Find Full Text PDF

Patients with Parkinson's disease and related disorders (PDRD) and their families have considerable unmet needs including non-motor symptom management, caregiver support, spiritual wellbeing, advance care planning, and end-of-life care. There is increasing interest in applying palliative care (PC) models to better meet these needs. While PC has been shown to improve care and quality of life (QOL) for people with cancer and heart failure, few studies have evaluated the role of PC for people with PDRD.

View Article and Find Full Text PDF

Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Drugs

March 2019

Division of Neurology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta Hospital, 7-112 Clinical Sciences Building, 11350-83 Ave, Edmonton, AB, T6G 2G3, Canada.

Article Synopsis
  • Myasthenia gravis is an autoimmune disease that causes muscle weakness due to autoantibodies targeting the neuromuscular junction, affecting various muscle-related proteins.
  • The disease can be categorized based on factors like age of onset, weakness patterns, autoantibody types, and thymic issues, with most patients benefiting from immunosuppressive therapies, though 15% remain difficult to treat.
  • Recent advancements in targeted B-cell therapies, including rituximab and eculizumab, have shown promise, though some studies have yielded mixed results, highlighting the need for further research and effective treatments.
View Article and Find Full Text PDF

Acute and reversible crying following deep brain stimulation targeting the globus pallidus interna in dystonia.

J Neurol Sci

May 2018

Parkinson and Movement Disorders Program, Division of Neurology, Department of Medicine, University of Alberta, 7-112 Clinical Sciences Building, 11350 - 83 Avenue Edmonton, Alberta T6G 2G3, Canada. Electronic address:

View Article and Find Full Text PDF